The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Effects of Testosterone on Cognition and Mood in Male Patients With Mild Alzheimer Disease and Healthy Elderly Men
Abstract
CONTEXT: There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD). OBJECTIVE: To evaluate the effects of testosterone therapy on cognition, neuropsychiatric symptoms, and quality of life in male patients with mild AD and healthy elderly men. DESIGN: Twenty-four-week, randomized, double-blind, placebo-controlled, parallel-group study. SETTING: Memory disorders clinics as well as general neurology and medicine clinics from University of California medical centers at Los Angeles, San Francisco, and Irvine. PATIENTS OR OTHER PARTICIPANTS: Sixteen male patients with AD and 22 healthy male control subjects. Healthy elderly control men were recruited from the community through advertisements as well as through the university-based clinics. INTERVENTION: Testosterone and placebo, in the form of hydroalcoholic gel (75 mg), were applied daily to the skin of the participants. MAIN OUTCOME MEASURES: Instruments assessing cognitive functioning (Alzheimer's Disease Assessment Scale-Cognitive Subscale, California Verbal Learning Test, Block Design Subtest, Judgment of Line Orientation, Developmental Test of Visual-Motor Integration), neuropsychiatric symptoms (Neuropsychiatric Inventory), global functioning (Clinician's Interview-Based Impression of Change), and quality of life (Quality of Life-Alzheimer Disease Scale). RESULTS: For the patients with AD, the testosterone-treated group had significantly greater improvements in the scores on the caregiver version of the quality-of-life scale (P = .01). No significant treatment group differences were detected in the cognitive scores at end of study, although numerically greater improvement or less decline on measures of visuospatial functions was demonstrated with testosterone treatment compared with placebo. In the healthy control group, a nonsignificant trend toward greater improvement in self-rated quality of life was observed in the testosterone-treated group (P = .09) compared with placebo treatment. No difference between the treatment groups was detected in the remaining outcome measures. Testosterone treatment was well tolerated with few adverse effects relative to placebo. CONCLUSIONS: Results suggest that testosterone replacement therapy improved overall quality of life in patients with AD. Testosterone had minimal effects on cognition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Self-citationLongitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 1×
“Male aging is associated with a gradual, progressive decline in serum levels of total testosterone, bioavailable testosterone, and free testosterone.(27) The gradual decline in testosterone level is associated with decreased muscle mass and strength, osteoporosis, decreased libido, mood alterations, and changes in cog…”
BackgroundAssessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Andropause: clinical implications of the decline in serum testosterone levels with aging in men
Matsumoto, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.2.m76 · Cited by 490 · cited 1×
“Several studies have reported positive associations between testosterone level and spatial cognitive function and memory for verbal and visual stimuli in older men.(16-21) In small, placebocontrolled clinical trials of relatively short duration (1 to 12 months), testosterone supplementation was reported to improve spa…”
BackgroundEstrogen use and verbal memory in healthy postmenopausal women
KAMPEN, D. L., & SHERWIN, B. B. (1994) · Obstetrics & Gynecology · doi:10.1097/00006250-199406000-00017 · Cited by 394
The role of aromatization in testosterone supplementation: Effects on cognition in older men
Cherrier, M. M., Matsumoto, A. M., Amory, J. K., Ahmed, S., Bremner, W., Peskind, E. R., Raskind, M. A., Johnson, M., & Craft, S. (2005) · Neurology · doi:10.1212/01.wnl.0000149639.25136.ca · Cited by 226
Estrogen replacement therapy in older women: a neuropsychological and brain MRI study
Schmidt, R., Fazekas, F., Reinhart, B., Kapeller, P., Fazekas, G., Offenbacher, H., Eber, B., Schumacher, M., & Freidl, W. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb01400.x · Cited by 205
Cited by
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationA review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Sex differences in cognitive impairment and Alzheimer’s disease
Li, R., & Singh, M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.002 · Cited by 527
Protective actions of sex steroid hormones in Alzheimer’s disease
Pike, C. J., Carroll, J. C., Rosario, E. R., & Barron, A. M. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.04.015 · Cited by 522
Emmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008) · JAMA · doi:10.1001/jama.2007.51 · Cited by 518
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 371
The benefits and risks of testosterone replacement therapy: a review
Morley, J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3025 · Cited by 369
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Corona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297
“6 Clinical trial report results Out of 2747 retrieved articles, 74 were included in the study (Figure 1) [11,31-42,44-102].”
BackgroundThe robust reliability of neuropsychological measures: meta-analyses of test-retest correlations
Calamia, M., Markon, K., & Tranel, D. (2013) · The Clinical Neuropsychologist · doi:10.1080/13854046.2013.809795 · Cited by 207
Testosterone for the aging male; current evidence and recommended practice
Jones, H. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s190 · Cited by 204
Sex and Gender Differences in Central Nervous System-Related Disorders
Zagni, E., Simoni, L., & Colombo, D. (2016) · Neuroscience Journal · doi:10.1155/2016/2827090 · Cited by 173
“[99] failed to note any beneficial effects of testosterone.”
BackgroundRisks and benefits of testosterone therapy in older men
Spitzer, M., Huang, G., Basaria, S., Travison, T. G., & Bhasin, S. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.73 · Cited by 154
Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies
Corona, G., Rastrelli, G., Di Pasquale, G., Sforza, A., Mannucci, E., & Maggi, M. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.04.641 · Cited by 138
Treatment of Men for “Low Testosterone”: A Systematic Review
Huo, S., Scialli, A. R., McGarvey, S., Hill, E., Tügertimur, B., Hogenmiller, A., Hirsch, A. I., & Fugh-Berman, A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162480 · Cited by 97
Male late-onset hypogonadism: pathogenesis, diagnosis and treatment
Huhtaniemi, I., & Forti, G. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.47 · Cited by 88
Testosterone Treatment of Men With Mild Cognitive Impairment and Low Testosterone Levels
Cherrier, M. M., Anderson, K., Shofer, J., Millard, S., & Matsumoto, A. M. (2015) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317514556874 · Cited by 71
Yeap, B. B., Almeida, O. P., Hyde, Z., Chubb, S. A. P., Hankey, G. J., Jamrozik, K., & Flicker, L. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03055.x · Cited by 65
Late-Life Onset Hypogonadism: A Review
Bassil, N., & Morley, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.02.003 · Cited by 59
“However, in patients with Alzheimer disease, testosterone treatment appeared to improve quality of life without affecting measures of cognition.(144) In a randomized, placebo-controlled, crossover trial, intramuscular testosterone therapy resulted in decreased verbal memory.”
Sleep, Sex Steroid Hormones, Sexual Activities, and Aging in Asian Men
Goh, V. H. ‐., & Tong, T. Y. ‐. (2010) · Journal of Andrology · doi:10.2164/jandrol.109.007856 · Cited by 47
Progress in the development of new drugs in Alzheimer's disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0012-x · Cited by 32
Testosterone therapy in older men with late-onset hypogonadism: a counter-rationale
Basaria, S. (2013) · Endocrine Practice · doi:10.4158/ep13318.ra · Cited by 18
Metadata
- Authors
- Lu, P. H., Masterman, D. A., Mulnard, R., Cotman, C., Miller, B., Yaffe, K., Reback, E., Porter, V., Swerdloff, R., & Cummings, J. L.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-02-01
- Volume
- 63
- Issue
- 2
- Pages
- 177
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2047985468
- Cited by
- 197
- References
- 8
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.